The Institute's COVID-19 Research Program

There are three major countermeasures against coronavirus that the Institute is leading the research effort or help co-develop:


(1) The Institute, in collaboration with Cellular Engineering Technologies, will develop ethical cell lines to replace the HEK293 cells and PER.C6 to assist pharmaceutical companies develop replication-incompetent adenovirus vectors vaccines if industry so chooses. 

(2) An off-the-shelf antiviral therapy against COVID-19 and future coronaviruses and other viruses.

(3) A platform based on our cell technology to create a live attenuated vaccine against COVID-19.

(4) A functional diagnostic using clinically-relevant cell-based and cell-free assays to predict adequate protective immunity against COVID-19.

© 2020 John Paul II Medical Research Institute.


John Paul II Medical Research Institute
2500 Crosspark Rd

Suite W230
Coralville, IA 52241

Phone: (319) 688-7367

Fax: (319) 887-2870